Vestibular tumor: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 3: Line 3:
{{CMG}} ; {{AE}} {{ADG}}
{{CMG}} ; {{AE}} {{ADG}}
==Overview==
==Overview==
'''Vestibular [[tumor]]s''' are growths that tend to develop underneath the [[serous]] tissue of the sublinguinal region. They may be found anywhere between the chin and the [[larynx]] (or voicebox) and are not more inclined to one side of the body than the other. They are predominantly present in adolescent females though they are not directly related to any hygienal issues. While [[surgery]] is the most often cure, deaths rarely occur due to the existence of vestibular tumors.
'''Vestibular [[tumor]]s''' are growths that tend to develop in or outside the auditory canal. They may be found anywhere between the chin and the [[larynx]] (or voicebox) and are not more inclined to one side of the body than the other. They are predominantly present in adolescent females though they are not directly related to any hygienal issues. While [[surgery]] is the most often cure, deaths rarely occur due to the existence of vestibular tumors.


==Historical Perspective==
==Historical Perspective==
The first reported case of a vestibular tumor was in 1898 in [[Lancaster, Pennsylvania]]. Though there have been stories of growths of the like of vestibular tumors, this was the first medically reported case. At the time, surgery was too dangerous, so Emilia Walfen was forced to live with the tumor, which eventually grew to the size of a [[Concord grape]].
The first reported case of a vestibular tumor was in 1898 in Lancaster, Pennsylvania. Though there have been stories of growths of the like of vestibular tumors, this was the first medically reported case. At the time, surgery was too dangerous, so Emilia Walfen was forced to live with the tumor, which eventually grew to the size of a [[Concord grape]].


== Pathogenesis ==
== Pathogenesis ==
Recent studies in NF2 patients led to the identification of the neurofibromin 2 gene, which is located on chromosome 22. The ''NF2'' gene produces merlin, also known as schwannomin, a cell membrane-related protein that acts as a tumor suppressor. Biallelic inactivation of the ''NF2'' gene is found in most sporadic vestibular schwannomas.
Recent studies in [[NF2 gene|NF2]] patients led to the identification of the [[NF2 gene|neurofibromin 2 gene]], which is located on [[chromosome 22]]. The [[NF2 gene|''NF2'' gene]] produces [[Merlin (protein)|merlin]], also known as schwannomin, a cell membrane-related protein that acts as a tumor suppressor. Bi-[[Allele|allelic]] inactivation of the [[NF2 gene|''NF2'' gene]] is found in most sporadic vestibular schwannomas.


=== Microscopic pathology ===
=== Microscopic pathology ===
* Vestibular schwannomas arise from perineural elements of the Schwann cell.  
* Vestibular schwannomas arise from perineural elements of the [[Schwann cell]].
* They occur with equal frequency on the superior and inferior branches of the vestibular nerve.
* They occur with equal frequency on the superior and inferior branches of the [[vestibular nerve]].
* Microscopically, zones of alternately dense and sparse cellularity, called Antoni A and B areas, respectively, are characteristic of vestibular schwannomas.  
* Microscopically, zones of alternately dense and sparse [[Cell (biology)|cellularity]], called Antoni A and B areas, respectively, are characteristic of vestibular schwannomas.
* Malignant degeneration is extremely rare, with only six cases having been reported.
* Malignant degeneration is extremely rare, with only six cases having been reported.
* Immunohistochemical staining for S100 protein is usually positive in both the benign and the rare malignant forms of this tumor.
*[[Immunohistochemistry|Immunohistochemical]] staining for S100 protein is usually positive in both the benign and the rare malignant forms of this [[tumor]].


== Differentiating Vestibular schwannoma from other diseases ==
== Differentiating Vestibular schwannoma from other diseases ==
Line 44: Line 44:
! colspan="11" style="background: #7d7d7d; color: #FFFFFF; padding: 5px; text-align: center;" |Adult primary brain tumors
! colspan="11" style="background: #7d7d7d; color: #FFFFFF; padding: 5px; text-align: center;" |Adult primary brain tumors
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Meningioma]]<br><ref name="pmid1642904">{{cite journal |vauthors=Zee CS, Chin T, Segall HD, Destian S, Ahmadi J |title=Magnetic resonance imaging of meningiomas |journal=Semin. Ultrasound CT MR |volume=13 |issue=3 |pages=154–69 |date=June 1992 |pmid=1642904 |doi= |url=}}</ref><ref name="pmid25744347">{{cite journal |vauthors=Shibuya M |title=Pathology and molecular genetics of meningioma: recent advances |journal=Neurol. Med. Chir. (Tokyo) |volume=55 |issue=1 |pages=14–27 |date=2015 |pmid=25744347 |doi=10.2176/nmc.ra.2014-0233 |url=}}</ref><ref name="pmid17509660">{{cite journal |vauthors=Begnami MD, Palau M, Rushing EJ, Santi M, Quezado M |title=Evaluation of NF2 gene deletion in sporadic schwannomas, meningiomas, and ependymomas by chromogenic in situ hybridization |journal=Hum. Pathol. |volume=38 |issue=9 |pages=1345–50 |date=September 2007 |pmid=17509660 |pmc=2094208 |doi=10.1016/j.humpath.2007.01.027 |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Meningioma]]<br>
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
Line 72: Line 72:
* May be associated with [[Neurofibromatosis type II|NF-2]]
* May be associated with [[Neurofibromatosis type II|NF-2]]
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Glioblastoma multiforme]]<br><ref name="pmid17964028">{{cite journal |vauthors=Sathornsumetee S, Rich JN, Reardon DA |title=Diagnosis and treatment of high-grade astrocytoma |journal=Neurol Clin |volume=25 |issue=4 |pages=1111–39, x |date=November 2007 |pmid=17964028 |doi=10.1016/j.ncl.2007.07.004 |url=}}</ref><ref name="pmid22819718">{{cite journal |vauthors=Pedersen CL, Romner B |title=Current treatment of low grade astrocytoma: a review |journal=Clin Neurol Neurosurg |volume=115 |issue=1 |pages=1–8 |date=January 2013 |pmid=22819718 |doi=10.1016/j.clineuro.2012.07.002 |url=}}</ref><ref name=":0">{{cite book | last = Mattle | first = Heinrich | title = Fundamentals of neurology : an illustrated guide | publisher = Thieme | location = Stuttgart New York | year = 2017 | isbn = 9783131364524 }}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Glioblastoma multiforme]]<br>
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
Line 106: Line 106:
* Most of the time, focal [[neurological]] deficit is the presenting [[Sign (medical)|sign]].
* Most of the time, focal [[neurological]] deficit is the presenting [[Sign (medical)|sign]].
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Oligodendroglioma]]<br><ref name="pmid26849038">{{cite journal |vauthors=Smits M |title=Imaging of oligodendroglioma |journal=Br J Radiol |volume=89 |issue=1060 |pages=20150857 |date=2016 |pmid=26849038 |pmc=4846213 |doi=10.1259/bjr.20150857 |url=}}</ref><ref name="pmid25943885">{{cite journal |vauthors=Wesseling P, van den Bent M, Perry A |title=Oligodendroglioma: pathology, molecular mechanisms and markers |journal=Acta Neuropathol. |volume=129 |issue=6 |pages=809–27 |date=June 2015 |pmid=25943885 |pmc=4436696 |doi=10.1007/s00401-015-1424-1 |url=}}</ref><ref name="pmid26478444">{{cite journal |vauthors=Kerkhof M, Benit C, Duran-Pena A, Vecht CJ |title=Seizures in oligodendroglial tumors |journal=CNS Oncol |volume=4 |issue=5 |pages=347–56 |date=2015 |pmid=26478444 |pmc=6082346 |doi=10.2217/cns.15.29 |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Oligodendroglioma]]<br>
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
Line 133: Line 133:
* Most of the time, [[epileptic seizure]] is the presenting [[Sign (medicine)|sign]].
* Most of the time, [[epileptic seizure]] is the presenting [[Sign (medicine)|sign]].
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hemangioblastoma]]<br><ref name="pmid24579662">{{cite journal |vauthors=Lonser RR, Butman JA, Huntoon K, Asthagiri AR, Wu T, Bakhtian KD, Chew EY, Zhuang Z, Linehan WM, Oldfield EH |title=Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease |journal=J. Neurosurg. |volume=120 |issue=5 |pages=1055–62 |date=May 2014 |pmid=24579662 |pmc=4762041 |doi=10.3171/2014.1.JNS131431 |url=}}</ref><ref name="pmid17877533">{{cite journal |vauthors=Hussein MR |title=Central nervous system capillary haemangioblastoma: the pathologist's viewpoint |journal=Int J Exp Pathol |volume=88 |issue=5 |pages=311–24 |date=October 2007 |pmid=17877533 |pmc=2517334 |doi=10.1111/j.1365-2613.2007.00535.x |url=}}</ref><ref name="pmid2704812">{{cite journal |vauthors=Lee SR, Sanches J, Mark AS, Dillon WP, Norman D, Newton TH |title=Posterior fossa hemangioblastomas: MR imaging |journal=Radiology |volume=171 |issue=2 |pages=463–8 |date=May 1989 |pmid=2704812 |doi=10.1148/radiology.171.2.2704812 |url=}}</ref><ref name="pmid945331">{{cite journal |vauthors=Perks WH, Cross JN, Sivapragasam S, Johnson P |title=Supratentorial haemangioblastoma with polycythaemia |journal=J. Neurol. Neurosurg. Psychiatry |volume=39 |issue=3 |pages=218–20 |date=March 1976 |pmid=945331 |doi= |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hemangioblastoma]]<br>
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
Line 154: Line 154:
* May be associated with [[Von Hippel-Lindau Disease|von hippel-lindau syndrome]]
* May be associated with [[Von Hippel-Lindau Disease|von hippel-lindau syndrome]]
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pituitary adenoma]]<br><ref name="pmid3786729">{{cite journal |vauthors=Kucharczyk W, Davis DO, Kelly WM, Sze G, Norman D, Newton TH |title=Pituitary adenomas: high-resolution MR imaging at 1.5 T |journal=Radiology |volume=161 |issue=3 |pages=761–5 |date=December 1986 |pmid=3786729 |doi=10.1148/radiology.161.3.3786729 |url=}}</ref><ref name="pmid22584705">{{cite journal |vauthors=Syro LV, Scheithauer BW, Kovacs K, Toledo RA, Londoño FJ, Ortiz LD, Rotondo F, Horvath E, Uribe H |title=Pituitary tumors in patients with MEN1 syndrome |journal=Clinics (Sao Paulo) |volume=67 Suppl 1 |issue= |pages=43–8 |date=2012 |pmid=22584705 |pmc=3328811 |doi= |url=}}</ref><ref name=":0" />
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pituitary adenoma]]<br><ref name=":0" />
| style="background: #F5F5F5; padding: 5px; text-align: center;" | −
| style="background: #F5F5F5; padding: 5px; text-align: center;" | −
| style="background: #F5F5F5; padding: 5px; text-align: center;" | −
| style="background: #F5F5F5; padding: 5px; text-align: center;" | −
Line 177: Line 177:
*  
*  
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Schwannoma]]<br><ref name="DonnellyDaly2007">{{cite journal|last1=Donnelly|first1=Martin J.|last2=Daly|first2=Carmel A.|last3=Briggs|first3=Robert J. S.|title=MR imaging features of an intracochlear acoustic schwannoma|journal=The Journal of Laryngology & Otology|volume=108|issue=12|year=2007|issn=0022-2151|doi=10.1017/S0022215100129056}}</ref><ref name="pmid9639114">{{cite journal |vauthors=Feany MB, Anthony DC, Fletcher CD |title=Nerve sheath tumours with hybrid features of neurofibroma and schwannoma: a conceptual challenge |journal=Histopathology |volume=32 |issue=5 |pages=405–10 |date=May 1998 |pmid=9639114 |doi= |url=}}</ref><ref name="pmid28710469">{{cite journal |vauthors=Chen H, Xue L, Wang H, Wang Z, Wu H |title=Differential NF2 Gene Status in Sporadic Vestibular Schwannomas and its Prognostic Impact on Tumour Growth Patterns |journal=Sci Rep |volume=7 |issue=1 |pages=5470 |date=July 2017 |pmid=28710469 |doi=10.1038/s41598-017-05769-0 |url=}}</ref><ref name="HardellHansson Mild2003">{{cite journal|last1=Hardell|first1=Lennart|last2=Hansson Mild|first2=Kjell|last3=Sandström|first3=Monica|last4=Carlberg|first4=Michael|last5=Hallquist|first5=Arne|last6=Påhlson|first6=Anneli|title=Vestibular Schwannoma, Tinnitus and Cellular Telephones|journal=Neuroepidemiology|volume=22|issue=2|year=2003|pages=124–129|issn=0251-5350|doi=10.1159/000068745}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Schwannoma]]<br>
| style="background: #F5F5F5; padding: 5px; text-align: center;" | −
| style="background: #F5F5F5; padding: 5px; text-align: center;" | −
| style="background: #F5F5F5; padding: 5px; text-align: center;" | −
| style="background: #F5F5F5; padding: 5px; text-align: center;" | −
Line 199: Line 199:
* May be associated with [[Neurofibromatosis type II|NF-2]] (bilateral [[Schwannoma|schwannomas]])
* May be associated with [[Neurofibromatosis type II|NF-2]] (bilateral [[Schwannoma|schwannomas]])
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Primary central nervous system lymphoma|Primary CNS lymphoma]]<br><ref name="pmid7480733">{{cite journal |vauthors=Chinn RJ, Wilkinson ID, Hall-Craggs MA, Paley MN, Miller RF, Kendall BE, Newman SP, Harrison MJ |title=Toxoplasmosis and primary central nervous system lymphoma in HIV infection: diagnosis with MR spectroscopy |journal=Radiology |volume=197 |issue=3 |pages=649–54 |date=December 1995 |pmid=7480733 |doi=10.1148/radiology.197.3.7480733 |url=}}</ref><ref name="Paulus19992">{{cite journal|last1=Paulus|first1=Werner|journal=Journal of Neuro-Oncology|title=Classification, Pathogenesis and Molecular Pathology of Primary CNS Lymphomas|volume=43|issue=3|year=1999|pages=203–208|issn=0167594X|doi=10.1023/A:1006242116122}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Primary central nervous system lymphoma|Primary CNS lymphoma]]<br>
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
Line 223: Line 223:
! colspan="11" style="background: #7d7d7d; color: #FFFFFF; padding: 5px; text-align: center;" |Childhood primary brain tumors
! colspan="11" style="background: #7d7d7d; color: #FFFFFF; padding: 5px; text-align: center;" |Childhood primary brain tumors
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pilocytic astrocytoma]]<br><ref name="pmid179640282">{{cite journal |vauthors=Sathornsumetee S, Rich JN, Reardon DA |title=Diagnosis and treatment of high-grade astrocytoma |journal=Neurol Clin |volume=25 |issue=4 |pages=1111–39, x |date=November 2007 |pmid=17964028 |doi=10.1016/j.ncl.2007.07.004 |url=}}</ref><ref name="pmid228197182">{{cite journal |vauthors=Pedersen CL, Romner B |title=Current treatment of low grade astrocytoma: a review |journal=Clin Neurol Neurosurg |volume=115 |issue=1 |pages=1–8 |date=January 2013 |pmid=22819718 |doi=10.1016/j.clineuro.2012.07.002 |url=}}</ref><ref name=":02">{{cite book | last = Mattle | first = Heinrich | title = Fundamentals of neurology : an illustrated guide | publisher = Thieme | location = Stuttgart New York | year = 2017 | isbn = 9783131364524 }}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pilocytic astrocytoma]]<br>
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
Line 246: Line 246:
* Most of the time, [[Cerebellum|cerebellar]] dysfunction is the presenting [[signs]].
* Most of the time, [[Cerebellum|cerebellar]] dysfunction is the presenting [[signs]].
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Medulloblastoma]]<br><ref name="DorwartWara1981">{{cite journal|last1=Dorwart|first1=R H|last2=Wara|first2=W M|last3=Norman|first3=D|last4=Levin|first4=V A|title=Complete myelographic evaluation of spinal metastases from medulloblastoma.|journal=Radiology|volume=139|issue=2|year=1981|pages=403–408|issn=0033-8419|doi=10.1148/radiology.139.2.7220886}}</ref><ref name="Fruehwald-PallamarPuchner2011">{{cite journal|last1=Fruehwald-Pallamar|first1=Julia|last2=Puchner|first2=Stefan B.|last3=Rossi|first3=Andrea|last4=Garre|first4=Maria L.|last5=Cama|first5=Armando|last6=Koelblinger|first6=Claus|last7=Osborn|first7=Anne G.|last8=Thurnher|first8=Majda M.|title=Magnetic resonance imaging spectrum of medulloblastoma|journal=Neuroradiology|volume=53|issue=6|year=2011|pages=387–396|issn=0028-3940|doi=10.1007/s00234-010-0829-8}}</ref><ref name="BurgerGrahmann1987">{{cite journal|last1=Burger|first1=P. C.|last2=Grahmann|first2=F. C.|last3=Bliestle|first3=A.|last4=Kleihues|first4=P.|title=Differentiation in the medulloblastoma|journal=Acta Neuropathologica|volume=73|issue=2|year=1987|pages=115–123|issn=0001-6322|doi=10.1007/BF00693776}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Medulloblastoma]]<br>
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
Line 268: Line 268:
* [[Drop metastasis]] ([[metastasis]] through [[CSF]])
* [[Drop metastasis]] ([[metastasis]] through [[CSF]])
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Ependymoma]]<br><ref name="YuhBarkovich2009">{{cite journal|last1=Yuh|first1=E. L.|last2=Barkovich|first2=A. J.|last3=Gupta|first3=N.|title=Imaging of ependymomas: MRI and CT|journal=Child's Nervous System|volume=25|issue=10|year=2009|pages=1203–1213|issn=0256-7040|doi=10.1007/s00381-009-0878-7}}</ref><ref name=":0" />
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Ependymoma]]<br><ref name=":0" />
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
Line 291: Line 291:
* Causes an unusually persistent, continuous [[headache]] in children.
* Causes an unusually persistent, continuous [[headache]] in children.
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Craniopharyngioma]]<br><ref name="pmid12407316">{{cite journal |vauthors=Brunel H, Raybaud C, Peretti-Viton P, Lena G, Girard N, Paz-Paredes A, Levrier O, Farnarier P, Manera L, Choux M |title=[Craniopharyngioma in children: MRI study of 43 cases] |language=French |journal=Neurochirurgie |volume=48 |issue=4 |pages=309–18 |date=September 2002 |pmid=12407316 |doi= |url=}}</ref><ref name="PrabhuBrown2005">{{cite journal|last1=Prabhu|first1=Vikram C.|last2=Brown|first2=Henry G.|title=The pathogenesis of craniopharyngiomas|journal=Child's Nervous System|volume=21|issue=8-9|year=2005|pages=622–627|issn=0256-7040|doi=10.1007/s00381-005-1190-9}}</ref><ref name="pmid766825">{{cite journal |vauthors=Kennedy HB, Smith RJ |title=Eye signs in craniopharyngioma |journal=Br J Ophthalmol |volume=59 |issue=12 |pages=689–95 |date=December 1975 |pmid=766825 |pmc=1017436 |doi= |url=}}</ref><ref name=":0" />
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Craniopharyngioma]]<br><ref name=":0" />
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
Line 312: Line 312:
* Initialy presents with lower bitemporal quadrantanopsia followed by [[Bitemporal hemianopia|bitemporal hemianopsia]] (pressure on [[Optic chiasm|optic chiasma]] from above)
* Initialy presents with lower bitemporal quadrantanopsia followed by [[Bitemporal hemianopia|bitemporal hemianopsia]] (pressure on [[Optic chiasm|optic chiasma]] from above)
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pinealoma]]<br><ref name="pmid6625640">{{cite journal |vauthors=Ahmed SR, Shalet SM, Price DA, Pearson D |title=Human chorionic gonadotrophin secreting pineal germinoma and precocious puberty |journal=Arch. Dis. Child. |volume=58 |issue=9 |pages=743–5 |date=September 1983 |pmid=6625640 |doi= |url=}}</ref><ref name="Sano1976">{{cite journal|last1=Sano|first1=Keiji|title=Pinealoma in Children|journal=Pediatric Neurosurgery|volume=2|issue=1|year=1976|pages=67–72|issn=1016-2291|doi=10.1159/000119602}}</ref><ref name="Baggenstoss1939">{{cite journal|last1=Baggenstoss|first1=Archie H.|title=PINEALOMAS|journal=Archives of Neurology And Psychiatry|volume=41|issue=6|year=1939|pages=1187|issn=0096-6754|doi=10.1001/archneurpsyc.1939.02270180115011}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pinealoma]]<br>
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
Line 331: Line 331:
! colspan="11" style="background: #7d7d7d; color: #FFFFFF; padding: 5px; text-align: center;" |Vascular
! colspan="11" style="background: #7d7d7d; color: #FFFFFF; padding: 5px; text-align: center;" |Vascular
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Arteriovenous malformation|AV malformation]]<br><ref name="KucharczykLemme-Pleghos1985">{{cite journal|last1=Kucharczyk|first1=W|last2=Lemme-Pleghos|first2=L|last3=Uske|first3=A|last4=Brant-Zawadzki|first4=M|last5=Dooms|first5=G|last6=Norman|first6=D|title=Intracranial vascular malformations: MR and CT imaging.|journal=Radiology|volume=156|issue=2|year=1985|pages=383–389|issn=0033-8419|doi=10.1148/radiology.156.2.4011900}}</ref><ref name="FleetwoodSteinberg2002">{{cite journal|last1=Fleetwood|first1=Ian G|last2=Steinberg|first2=Gary K|title=Arteriovenous malformations|journal=The Lancet|volume=359|issue=9309|year=2002|pages=863–873|issn=01406736|doi=10.1016/S0140-6736(02)07946-1}}</ref><ref name=":0" />
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Arteriovenous malformation|AV malformation]]<br><ref name=":0" />
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
Line 348: Line 348:
* We may see bag of worms appearance in [[CT angiography]]
* We may see bag of worms appearance in [[CT angiography]]
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Brain aneurysm]]<br><ref name="ChapmanRubinstein1992">{{cite journal|last1=Chapman|first1=Arlene B.|last2=Rubinstein|first2=David|last3=Hughes|first3=Richard|last4=Stears|first4=John C.|last5=Earnest|first5=Michael P.|last6=Johnson|first6=Ann M.|last7=Gabow|first7=Patricia A.|last8=Kaehny|first8=William D.|title=Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease|journal=New England Journal of Medicine|volume=327|issue=13|year=1992|pages=916–920|issn=0028-4793|doi=10.1056/NEJM199209243271303}}</ref><ref name="pmid25632331">{{cite journal |vauthors=Castori M, Voermans NC |title=Neurological manifestations of Ehlers-Danlos syndrome(s): A review |journal=Iran J Neurol |volume=13 |issue=4 |pages=190–208 |date=October 2014 |pmid=25632331 |pmc=4300794 |doi= |url=}}</ref><ref name="SchievinkRaissi2010">{{cite journal|last1=Schievink|first1=W. I.|last2=Raissi|first2=S. S.|last3=Maya|first3=M. M.|last4=Velebir|first4=A.|title=Screening for intracranial aneurysms in patients with bicuspid aortic valve|journal=Neurology|volume=74|issue=18|year=2010|pages=1430–1433|issn=0028-3878|doi=10.1212/WNL.0b013e3181dc1acf}}</ref><ref name="pmid28486967">{{cite journal |vauthors=Germain DP |title=Pseudoxanthoma elasticum |journal=Orphanet J Rare Dis |volume=12 |issue=1 |pages=85 |date=May 2017 |pmid=28486967 |pmc=5424392 |doi=10.1186/s13023-017-0639-8 |url=}}</ref><ref name="pmid27162847">{{cite journal |vauthors=Farahmand M, Farahangiz S, Yadollahi M |title=Diagnostic Accuracy of Magnetic Resonance Angiography for Detection of Intracranial Aneurysms in Patients with Acute Subarachnoid Hemorrhage; A Comparison to Digital Subtraction Angiography |journal=Bull Emerg Trauma |volume=1 |issue=4 |pages=147–51 |date=October 2013 |pmid=27162847 |pmc=4789449 |doi= |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Brain aneurysm]]<br>
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
Line 367: Line 367:
! colspan="11" style="background: #7d7d7d; color: #FFFFFF; padding: 5px; text-align: center;" |Infectious
! colspan="11" style="background: #7d7d7d; color: #FFFFFF; padding: 5px; text-align: center;" |Infectious
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Bacterial [[brain abscess]]<br><ref name="HaimesZimmerman1989">{{cite journal|last1=Haimes|first1=AB|last2=Zimmerman|first2=RD|last3=Morgello|first3=S|last4=Weingarten|first4=K|last5=Becker|first5=RD|last6=Jennis|first6=R|last7=Deck|first7=MD|title=MR imaging of brain abscesses|journal=American Journal of Roentgenology|volume=152|issue=5|year=1989|pages=1073–1085|issn=0361-803X|doi=10.2214/ajr.152.5.1073}}</ref><ref name="BrouwerTunkel2014">{{cite journal|last1=Brouwer|first1=Matthijs C.|last2=Tunkel|first2=Allan R.|last3=McKhann|first3=Guy M.|last4=van de Beek|first4=Diederik|title=Brain Abscess|journal=New England Journal of Medicine|volume=371|issue=5|year=2014|pages=447–456|issn=0028-4793|doi=10.1056/NEJMra1301635}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Bacterial [[brain abscess]]<br>
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
Line 387: Line 387:
* The most common causes of [[brain abscess]] are [[Streptococcus]] and [[Staphylococcus]].
* The most common causes of [[brain abscess]] are [[Streptococcus]] and [[Staphylococcus]].
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Tuberculosis]]<br><ref name="MorgadoRuivo2005">{{cite journal|last1=Morgado|first1=Carlos|last2=Ruivo|first2=Nuno|title=Imaging meningo-encephalic tuberculosis|journal=European Journal of Radiology|volume=55|issue=2|year=2005|pages=188–192|issn=0720048X|doi=10.1016/j.ejrad.2005.04.017}}</ref><ref name=":0" /><ref name="pmid19275620">{{cite journal |vauthors=Be NA, Kim KS, Bishai WR, Jain SK |title=Pathogenesis of central nervous system tuberculosis |journal=Curr. Mol. Med. |volume=9 |issue=2 |pages=94–9 |date=March 2009 |pmid=19275620 |pmc=4486069 |doi= |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Tuberculosis]]<br><ref name=":0" />
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
Line 408: Line 408:
* It is associated with [[HIV]] [[infection]]
* It is associated with [[HIV]] [[infection]]
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Toxoplasmosis]]<br><ref name="pmid74807332">{{cite journal |vauthors=Chinn RJ, Wilkinson ID, Hall-Craggs MA, Paley MN, Miller RF, Kendall BE, Newman SP, Harrison MJ |title=Toxoplasmosis and primary central nervous system lymphoma in HIV infection: diagnosis with MR spectroscopy |journal=Radiology |volume=197 |issue=3 |pages=649–54 |date=December 1995 |pmid=7480733 |doi=10.1148/radiology.197.3.7480733 |url=}}</ref><ref name="pmid27348541">{{cite journal |vauthors=Helton KJ, Maron G, Mamcarz E, Leventaki V, Patay Z, Sadighi Z |title=Unusual magnetic resonance imaging presentation of post-BMT cerebral toxoplasmosis masquerading as meningoencephalitis and ventriculitis |journal=Bone Marrow Transplant. |volume=51 |issue=11 |pages=1533–1536 |date=November 2016 |pmid=27348541 |doi=10.1038/bmt.2016.168 |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Toxoplasmosis]]<br>
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
Line 426: Line 426:
* It is associated with [[HIV]] [[infection]]
* It is associated with [[HIV]] [[infection]]
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hydatid cyst]]<br><ref name="pmid27620198">{{cite journal |vauthors=Taslakian B, Darwish H |title=Intracranial hydatid cyst: imaging findings of a rare disease |journal=BMJ Case Rep |volume=2016 |issue= |pages= |date=September 2016 |pmid=27620198 |pmc=5030532 |doi=10.1136/bcr-2016-216570 |url=}}</ref><ref name=":0" />
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hydatid cyst]]<br><ref name=":0" />
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
Line 444: Line 444:
* [[Brain]], [[eye]], and [[Spleen|splenic]] [[Cyst|cysts]] may not produce detectable amount of [[antibodies]]
* [[Brain]], [[eye]], and [[Spleen|splenic]] [[Cyst|cysts]] may not produce detectable amount of [[antibodies]]
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[CNS]] [[cryptococcosis]]<br><ref name="pmid25006721">{{cite journal |vauthors=McCarthy M, Rosengart A, Schuetz AN, Kontoyiannis DP, Walsh TJ |title=Mold infections of the central nervous system |journal=N. Engl. J. Med. |volume=371 |issue=2 |pages=150–60 |date=July 2014 |pmid=25006721 |pmc=4840461 |doi=10.1056/NEJMra1216008 |url=}}</ref>  
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[CNS]] [[cryptococcosis]]<br>
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
Line 473: Line 473:
* Since [[brain]] [[Biopsy|biopsies]] are highly invasive and may may cause [[neurological]] deficits, we [[diagnose]] [[CNS]] [[fungal]] [[Infection|infections]] based on [[laboratory]] and imaging findings
* Since [[brain]] [[Biopsy|biopsies]] are highly invasive and may may cause [[neurological]] deficits, we [[diagnose]] [[CNS]] [[fungal]] [[Infection|infections]] based on [[laboratory]] and imaging findings
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[CNS]] [[aspergillosis]]<br><ref name="pmid250067212">{{cite journal |vauthors=McCarthy M, Rosengart A, Schuetz AN, Kontoyiannis DP, Walsh TJ |title=Mold infections of the central nervous system |journal=N. Engl. J. Med. |volume=371 |issue=2 |pages=150–60 |date=July 2014 |pmid=25006721 |pmc=4840461 |doi=10.1056/NEJMra1216008 |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[CNS]] [[aspergillosis]]<br>
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
Line 499: Line 499:
! colspan="11" style="background: #7d7d7d; color: #FFFFFF; padding: 5px; text-align: center;" |Other
! colspan="11" style="background: #7d7d7d; color: #FFFFFF; padding: 5px; text-align: center;" |Other
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Brain metastasis]]<br><ref name="pmid29307364">{{cite journal |vauthors=Pope WB |title=Brain metastases: neuroimaging |journal=Handb Clin Neurol |volume=149 |issue= |pages=89–112 |date=2018 |pmid=29307364 |pmc=6118134 |doi=10.1016/B978-0-12-811161-1.00007-4 |url=}}</ref><ref name=":0" />
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Brain metastasis]]<br><ref name=":0" />
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
Line 528: Line 528:


== Risk Factors ==
== Risk Factors ==
Common risk factors for the development of vestibular schwaomas include:
Common [[risk factors]] for the development of vestibular schwaomas include:
* Childhood exposure to low-dose radiation for benign conditions of the head and neck
* Childhood exposure to low-dose [[radiation]] for benign conditions of the head and neck
* Radiofrequency radiation from the use of mobile phones
*[[Radiofrequency]] exposure from the use of mobile phones
* Noise exposure  
* Excessive noise exposure


== Epidemiology and Demographics ==
== Epidemiology and Demographics ==


=== Incidence ===
=== Incidence ===
* The overall incidence of vestibular schwannomas is approximately 1 per 100,000 person-years in the United States.  
* The overall [[incidence]] of vestibular schwannomas is approximately 1 per 100,000 person-years in the United States.
* Bilateral vestibular schwannomas are primarily observed in patients with neurofibromatosis type 2 (NF2).
*[[Bilateral]] vestibular schwannomas are primarily observed in patients with [[neurofibromatosis type 2]] ([[Neurofibromatosis type II|NF2]]).
* The tumors are unilateral in more than 90 percent of cases, affecting the right and left sides with equal frequency.
* The [[tumors]] are unilateral in more than 90 percent of cases, affecting the right and left sides with equal frequency.


=== Age ===
=== Age ===
* The median age at diagnosis is approximately 50 years.  
* The [[median]] age at diagnosis is approximately 50 years.


=== Gender ===
=== Gender ===
Line 547: Line 547:


==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==
Vestibular schwanama pose a major health impediment if left untreated as they might cause pressure on adjacent posterior fossa structures such as cerebellum or brainstem and result in ataxia Brainstem compression, cerebellar tonsil herniation, hydrocephalus, and death can occur in untreated cases. Common complication include seizures and paralysis difficulty swallowing due to the pressure on the [[tongue]] or [[pharynx]]. The functions of the lower cranial nerves can also become impaired, leading to dysarthria, dysphagia, aspiration, and hoarseness.
Vestibular schwanama pose a major health impediment if left untreated as they might cause pressure on adjacent [[posterior fossa]] structures such as [[cerebellum]] or [[brainstem]] and result in [[ataxia]], [[brainstem]] compression, [[Cerebellar tonsill herniation|cerebellar tonsil herniation]], [[hydrocephalus]], and death can occur in untreated cases. Common [[Complication (medicine)|complication]] include [[seizures]] and paralysis [[difficulty swallowing]] due to the pressure on the [[tongue]] or [[pharynx]]. The functions of the lower [[cranial nerves]] can also become impaired, leading to [[dysarthria]], [[dysphagia]], [[aspiration]], and [[hoarseness]].


== Diagnosis ==
== Diagnosis ==


=== History and Symptoms ===
=== History and Symptoms ===
* Symptoms associated with vestibular schwannoma can be due to cranial nerve involvement, cerebellar compression, or tumor progression. Clinical manifestations in this series included the following:
*[[Symptoms]] associated with vestibular schwannoma can be due to [[Cranial nerves|cranial nerve]] involvement, [[Cerebellum|cerebellar]] compression, or [[tumor]] progression. Clinical manifestations in this series included the following:
{| class="wikitable"
{| class="wikitable"
|+
|+
Line 559: Line 559:
!Symtpoms
!Symtpoms
|-
|-
|Cochlear nerve
|[[Cochlear nerve]]
|95 percent
|95 percent
|
|
* Hearing loss
*[[Hearing loss]]


* Tinnitus
*[[Tinnitus]]
|-
|-
|Vestibular nerve
|[[Vestibular nerve]]
|61 percent
|61 percent
|
|
Line 572: Line 572:
* Brief tilting or veering
* Brief tilting or veering
|-
|-
|Trigeminal nerve  
|[[Trigeminal nerve]]
|17 percent
|17 percent
|
|
* Facial numbness (paresthesia), hypesthesia, and pain.
* Facial numbness ([[paresthesia]]), [[hypesthesia]], and [[pain]].
|-
|-
|Facial nerve
|[[Facial nerve]]
|6 percent
|6 percent
|
|
* Facial paresis  
*[[Facial paralysis|Facial paresis]]
* Taste disturbances (due to nervus intermedius impairment).  
* Taste disturbances (due to [[nervus intermedius]] impairment).
* Xerophthalmia
*[[Xerophthalmia]]
* Paroxysmal lacrimation
* Paroxysmal [[lacrimation]]
* Xerostomia
*[[Xerostomia]]
|-
|-
|Tumor progression
|[[Tumor]] progression
|
|
|
|
* Pressure on adjacent posterior fossa structures such as cerebellum or brainstem and result in ataxia
* Pressure on adjacent [[posterior fossa]] structures such as [[cerebellum]] or [[brainstem]] and result in [[ataxia]]
* Brainstem compression, cerebellar tonsil herniation, hydrocephalus, and death can occur in untreated cases
*[[Brainstem]] compression, [[Cerebellar tonsill herniation|cerebellar tonsil herniation]], [[hydrocephalus]], and death can occur in untreated cases
|}
|}


=== Physical Examination ===
=== Physical Examination ===
* Hearing tests are typically abnormal due to involvement of the acoustic nerve.  
* Hearing tests are typically abnormal due to involvement of the [[acoustic nerve]].  
** The Weber and Rinne tests may be useful in suggesting asymmetric sensorineural hearing impairment.
** The [[Weber test|Weber]] and [[Rinne test|Rinne tests]] may be useful in suggesting asymmetric [[sensorineural hearing impairment]].


* Neurologic examination may reveal other cranial nerve deficits
*[[Neurological|Neurologic]] examination may reveal other [[Cranial nerve disease|cranial nerve deficits]]
** A decreased or absent ipsilateral corneal reflex and facial twitching or hypesthesia may occur as cranial nerves V and VII become affected.
** A decreased or absent [[ipsilateral]] [[corneal reflex]] and facial [[twitching]] or [[hypesthesia]] may occur as [[Trigeminal nerve|cranial nerves V]] and [[Facial nerve|VII]] become affected.
** Romberg, Hall-Pike, and other common office balance tests are typically normal.
**[[Romberg's test|Romberg]], Hall-Pike, and other common office balance tests are typically normal.


=== CT ===
=== CT ===
Findings of vestibular schwanoma on CT include:
Findings of vestibular schwanoma on [[CT-scans|CT]] include:
* Erosion and widening of the internal acoustic canal.  
* Erosion and widening of the internal acoustic canal.  
* The density of these tumors on non-contrast imaging is variable, and often they are hard to see, especially on account of beam hardening and streak artefact from the adjacent petrous temporal bone.
* The density of these [[tumors]] on non-contrast imaging is variable, and often they are hard to see, especially on account of beam hardening and streak artefact from the adjacent [[petrous temporal bone]].


* Contrast enhancement is present but can be underwhelming, especially in larger lesions with cystic components.
*[[Contrast enhanced CT|Contrast enhancement]] is present but can be underwhelming, especially in larger lesions with cystic components.


=== MRI ===
=== MRI ===
MRI findings of vestibular schwanoma include:
[[MRI]] findings of vestibular schwanoma include:


{| class="wikitable"
{| class="wikitable"
Line 617: Line 617:
|'''T1'''
|'''T1'''
|
|
* Slightly hypointense to the adjacent brain.
* Slightly hypointense to the adjacent [[brain]].
* Isointense to the adjacent brain  
* Isointense to the adjacent [[brain]]
* May contain hypointense cystic areas
* May contain hypointense cystic areas
|-
|-
|'''T2'''
|'''T2'''
|
|
** Heterogeneously hyperintense to adjacent brain  
** Heterogeneously hyperintense to adjacent [[brain]]
** Fluid intensity cystic areas
** Fluid intensity cystic areas
** May have associated peritumoral arachnoid cysts  
** May have associated peritumoral [[arachnoid cysts]]
*
*
|-
|-
|'''T1 C+ (Gd)'''
|'''T1 C+ (Gd)'''
|Contrast enhancement is intense however, heterogeneous in larger tumors
|[[Contrast enhanced CT|Contrast enhancement]] is intense however, heterogeneous in larger [[tumors]]
|}
|}


=== Other Diagnostic Studies ===
=== Other Diagnostic Studies ===
'''Audiometry'''  
'''Audiometry'''  
* Audiometry is the best initial screening laboratory test for the diagnosis of vestibular schwannoma.  
*[[Audiometry]] is the best initial screening laboratory test for the [[diagnosis]] of vestibular schwannoma.
* Pure tone and speech audiometry should be performed in an acoustically shielded area.  
* Pure tone and speech [[audiometry]] should be performed in an acoustically shielded area.
* Test results typically show an asymmetric sensorineural hearing loss, usually more prominent in the higher frequencies.  
* Test results typically show an asymmetric [[sensorineural hearing loss]], usually more prominent in the higher frequencies.
* Hearing loss does not necessarily correlate with tumor size.  
* Hearing loss does not necessarily correlate with [[tumor]] size.
* The speech discrimination score is usually markedly reduced in the affected ear and out of proportion to the measured hearing loss.  
* The speech discrimination score is usually markedly reduced in the affected ear and out of proportion to the measured [[hearing loss]].
* Common audiometry tests that are of current practice include:
* Common audiometry tests that are of current practice include:
** Acoustic reflex testing,
**[[Acoustic reflex]] testing
** Impedance audiometry
** Impedance [[audiometry]]
** Bekesy audiometry.
** Bekesy [[audiometry]]
** Brainstem-evoked response audiometry (AER/ABR).
** Brainstem-evoked response [[audiometry]] (AER/ABR).
'''Vestibular testing'''
'''Vestibular testing'''
* Vestibular testing has limited utility as a screening test for the diagnosis of vestibular schwannoma because of the accuracy of evoked response audiometry.  
*[[Vestibular system|Vestibular]] testing has limited utility as a screening test for the diagnosis of vestibular schwannoma because of the accuracy of evoked response [[audiometry]].
* When testing is performed, a decreased or absent caloric response on the affected side may be seen. When the tumor is small, though, a normal response is often seen.
* When testing is performed, a decreased or absent caloric response on the affected side may be seen. When the [[tumor]] is small, though, a normal response is often seen.


**
**
Line 652: Line 652:


==Treatment==
==Treatment==
Treatment options for patients with a vestibular schwannoma include surgery and radiation therapy.
Treatment options for patients with a vestibular schwannoma include [[surgery]] and [[radiation therapy]].


=== Surgery ===
=== Surgery ===
Surgery generally results in satisfactory long-term control of vestibular schwannomas. There are three standard operative approaches.
[[Surgery]] generally results in satisfactory long-term control of vestibular schwannomas. There are three standard operative approaches.


{| class="wikitable"
{| class="wikitable"
Line 662: Line 662:
|-
|-
|Retromastoid suboccipital (retrosigmoid)  
|Retromastoid suboccipital (retrosigmoid)  
|The suboccipital approach can be used for any size tumor with or without attempted hearing preservation.
|The suboccipital approach can be used for any size [[tumor]] with or without attempted [[hearing]] preservation.
|-
|-
|Translabyrinthine
|Translabyrinthine
|The translabyrinthine approach has been recommended for acoustic tumors larger than 3 cm and for smaller tumors when hearing preservation is not an issue.
|The translabyrinthine approach has been recommended for acoustic [[tumors]] larger than 3 cm and for smaller [[tumors]] when hearing preservation is not an issue.
|-
|-
|Middle fossa  
|Middle fossa  
|The middle fossa approach is suitable for small (<1.5 cm) tumors when hearing preservation is a goal.
|The middle fossa approach is suitable for small (<1.5 cm) [[tumors]] when hearing preservation is a goal.
|}
|}


=== Radiation therapy ===
=== Radiation therapy ===
Radiation therapy for patients with vestibular schwannoma include stereotactic radiosurgery (SRS), stereotactic radiotherapy (SRT), and proton beam therapy, as well as conventional fractionated radiation therapy.
[[Radiation therapy]] for patients with vestibular schwannoma include [[stereotactic radiosurgery]] (SRS), stereotactic radiotherapy (SRT), and proton beam therapy, as well as conventional fractionated [[radiation therapy]].


{| class="wikitable"
{| class="wikitable"
Line 680: Line 680:
|'''Stereotactic radiosurgery'''
|'''Stereotactic radiosurgery'''
|
|
* SRS is a technique that utilizes multiple convergent beams to deliver a high single dose of radiation to a radiographically discrete treatment volume, thereby minimizing injury to adjacent structures.  
* SRS is a technique that utilizes multiple convergent beams to deliver a high single dose of [[radiation]] to a radiographically discrete treatment volume, thereby minimizing injury to adjacent structures.
* This can be accomplished with either the gamma knife or a linear accelerator.  
* This can be accomplished with either the [[Gamma Knife|gamma knife]] or a linear accelerator.
* Radiosurgery is a viable treatment option for selected patients with smaller tumors (<3 cm) or for enlarging tumors in patients who are not candidates for surgery
* Radiosurgery is a viable treatment option for selected patients with smaller [[tumors]] (<3 cm) or for enlarging [[tumors]] in patients who are not candidates for [[surgery]]
|-
|-
|'''Stereotactic radiotherapy'''
|'''Stereotactic radiotherapy'''
|
|
* Fractionated SRT utilizes focused doses of radiation given over a series of treatment sessions.  
* Fractionated SRT utilizes focused doses of radiation given over a series of treatment sessions.  
* The intent is to reduce radiation injury to critical neural structures while preserving tumor control.
* The intent is to reduce [[radiation]] injury to critical neural structures while preserving [[tumor]] control.
|-
|-
|'''Proton beam therapy'''
|'''Proton beam therapy'''
|
|
* Proton beam therapy may provide maximal local tumor control while minimizing cranial nerve injuries.  
* Proton beam therapy may provide maximal local [[tumor]] control while minimizing [[Cranial nerves|cranial nerve]] injuries.
* The physical characteristics of the beam result in the majority of the energy being deposited at the end of a linear track (the Bragg peak), with the dose falling rapidly to zero beyond the Bragg peak.
* The physical characteristics of the beam result in the majority of the energy being deposited at the end of a linear track (the Bragg peak), with the dose falling rapidly to zero beyond the Bragg peak.
* Thus, the use of proton beam therapy permits the delivery of high doses of radiation therapy to the target volume while limiting the "scatter" dose received by surrounding tissues.
* Thus, the use of proton beam therapy permits the delivery of high doses of [[radiation therapy]] to the target volume while limiting the "scatter" dose received by surrounding [[Tissue (biology)|tissues]].
|}
|}


Line 704: Line 704:
[[Category:Otolaryngology]]
[[Category:Otolaryngology]]
[[Category:Gastroenterology]]
[[Category:Gastroenterology]]
<references />

Revision as of 20:35, 22 October 2019

Template:Vestibular tumor Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

Vestibular tumors are growths that tend to develop in or outside the auditory canal. They may be found anywhere between the chin and the larynx (or voicebox) and are not more inclined to one side of the body than the other. They are predominantly present in adolescent females though they are not directly related to any hygienal issues. While surgery is the most often cure, deaths rarely occur due to the existence of vestibular tumors.

Historical Perspective

The first reported case of a vestibular tumor was in 1898 in Lancaster, Pennsylvania. Though there have been stories of growths of the like of vestibular tumors, this was the first medically reported case. At the time, surgery was too dangerous, so Emilia Walfen was forced to live with the tumor, which eventually grew to the size of a Concord grape.

Pathogenesis

Recent studies in NF2 patients led to the identification of the neurofibromin 2 gene, which is located on chromosome 22. The NF2 gene produces merlin, also known as schwannomin, a cell membrane-related protein that acts as a tumor suppressor. Bi-allelic inactivation of the NF2 gene is found in most sporadic vestibular schwannomas.

Microscopic pathology

  • Vestibular schwannomas arise from perineural elements of the Schwann cell.
  • They occur with equal frequency on the superior and inferior branches of the vestibular nerve.
  • Microscopically, zones of alternately dense and sparse cellularity, called Antoni A and B areas, respectively, are characteristic of vestibular schwannomas.
  • Malignant degeneration is extremely rare, with only six cases having been reported.
  • Immunohistochemical staining for S100 protein is usually positive in both the benign and the rare malignant forms of this tumor.

Differentiating Vestibular schwannoma from other diseases

The differential diagnosis includes meningioma, facial nerve schwannomas, gliomas, cholesterol cysts, cholesteatomas, hemangiomas, aneurysms, arachnoid cysts, lipomas, and metastatic tumor. For more information click here On the basis of seizure, visual disturbance, and constitutional symptoms, meningioma must be differentiated from oligodendroglioma, astrocytoma, hemangioblastoma, pituitary adenoma, schwannoma, primary CNS lymphoma, medulloblastoma, ependymoma, craniopharyngioma, pinealoma, AV malformation, brain aneurysm, bacterial brain abscess, tuberculosis, toxoplasmosis, hydatid cyst, CNS cryptococcosis, CNS aspergillosis, and brain metastasis.

Diseases Clinical manifestations Para-clinical findings Gold
standard
Additional findings
Symptoms Physical examination
Lab Findings MRI Immunohistopathology
Head-
ache
Seizure Visual disturbance Constitutional Focal neurological deficit
Adult primary brain tumors
Meningioma
+ +/− +/− +
  • Well circumscribed
  • Extra-axial mass
  • Whorled spindle cell pattern
  • May be associated with NF-2
Glioblastoma multiforme
+ +/− +/− +
  • Pseudopalisading appearance
Oligodendroglioma
+ + +/− +
  • Chicken wire capillary pattern
  • Fried egg cell appearance
Hemangioblastoma
+ +/− +/− +
Pituitary adenoma
[1]
+ Bitemporal hemianopia
  • It is associated with MEN1 disease.
Schwannoma
+
  • Split-fat sign
  • Fascicular sign
  • Often have areas of hemosiderin
  • S100+
Primary CNS lymphoma
+ +/− +/− +
  • Single mass with ring enhancement
Childhood primary brain tumors
Pilocytic astrocytoma
+ +/− +/− +
Medulloblastoma
+ +/− +/− +
  • Homer wright rosettes
Ependymoma
[1]
+ +/− +/− +
  • Hydrocephalus
  • Causes an unusually persistent, continuous headache in children.
Craniopharyngioma
[1]
+ +/− + Bitemporal hemianopia +
Pinealoma
+ +/− +/− + vertical gaze palsy
  • May cause prinaud syndrome (vertical gaze palsy, pupillary light-near dissociation, lid retraction and convergence-retraction nystagmus
Vascular
AV malformation
[1]
+ + +/− +/−
Brain aneurysm
+ +/− +/− +/−
  • MRA and CTA
Infectious
Bacterial brain abscess
+ +/− +/− + +
  • Central hypodense signal and surrounding ring-enhancement in T1
  • Central hyperintense area surrounded by a well-defined hypointense capsule with surrounding edema in T2
  • History/ imaging
Tuberculosis
[1]
+ +/− +/− + +
  • Lab data/ Imaging
Toxoplasmosis
+ +/− +/− +
  • History/ imaging
Hydatid cyst
[1]
+ +/− +/− +/− +
  • Imaging
CNS cryptococcosis
+ +/− +/− + +
  • We may see numerous acutely branching septate hyphae
  • Lab data/ Imaging
CNS aspergillosis
+ +/− +/− + +
  • Multiple abscesses
  • Ring enhancement
  • Peripheral low signal intensity on T2
  • We may see numerous acutely branching septate hyphae
  • Lab data/ Imaging
Other
Brain metastasis
[1]
+ +/− +/− + +
  • Based on the primary cancer type we may have different immunohistopathology findings.
  • History/ imaging

ABBREVIATIONS

CNS=Central nervous system, AV=Arteriovenous, CSF=Cerebrospinal fluid, NF-2=Neurofibromatosis type 2, MEN-1=Multiple endocrine neoplasia, GFAP=Glial fibrillary acidic protein, HIV=Human immunodeficiency virus, BhCG=Human chorionic gonadotropin, ESR=Erythrocyte sedimentation rate, AFB=Acid fast bacilli, MRA=Magnetic resonance angiography, CTA=CT angiography

Risk Factors

Common risk factors for the development of vestibular schwaomas include:

  • Childhood exposure to low-dose radiation for benign conditions of the head and neck
  • Radiofrequency exposure from the use of mobile phones
  • Excessive noise exposure

Epidemiology and Demographics

Incidence

  • The overall incidence of vestibular schwannomas is approximately 1 per 100,000 person-years in the United States.
  • Bilateral vestibular schwannomas are primarily observed in patients with neurofibromatosis type 2 (NF2).
  • The tumors are unilateral in more than 90 percent of cases, affecting the right and left sides with equal frequency.

Age

  • The median age at diagnosis is approximately 50 years.

Gender

  • Vestibular schwannomas occur equally in both genders.

Natural History, Complications, and Prognosis

Vestibular schwanama pose a major health impediment if left untreated as they might cause pressure on adjacent posterior fossa structures such as cerebellum or brainstem and result in ataxia, brainstem compression, cerebellar tonsil herniation, hydrocephalus, and death can occur in untreated cases. Common complication include seizures and paralysis difficulty swallowing due to the pressure on the tongue or pharynx. The functions of the lower cranial nerves can also become impaired, leading to dysarthria, dysphagia, aspiration, and hoarseness.

Diagnosis

History and Symptoms

  • Symptoms associated with vestibular schwannoma can be due to cranial nerve involvement, cerebellar compression, or tumor progression. Clinical manifestations in this series included the following:
Never involvement Incidence Symtpoms
Cochlear nerve 95 percent
Vestibular nerve 61 percent
  • Unsteadiness while walking
  • Brief tilting or veering
Trigeminal nerve 17 percent
Facial nerve 6 percent
Tumor progression

Physical Examination

CT

Findings of vestibular schwanoma on CT include:

  • Erosion and widening of the internal acoustic canal.
  • The density of these tumors on non-contrast imaging is variable, and often they are hard to see, especially on account of beam hardening and streak artefact from the adjacent petrous temporal bone.
  • Contrast enhancement is present but can be underwhelming, especially in larger lesions with cystic components.

MRI

MRI findings of vestibular schwanoma include:

MRI findings of Vestibular Schwanoma
T1
  • Slightly hypointense to the adjacent brain.
  • Isointense to the adjacent brain
  • May contain hypointense cystic areas
T2
    • Heterogeneously hyperintense to adjacent brain
    • Fluid intensity cystic areas
    • May have associated peritumoral arachnoid cysts
T1 C+ (Gd) Contrast enhancement is intense however, heterogeneous in larger tumors

Other Diagnostic Studies

Audiometry

  • Audiometry is the best initial screening laboratory test for the diagnosis of vestibular schwannoma.
  • Pure tone and speech audiometry should be performed in an acoustically shielded area.
  • Test results typically show an asymmetric sensorineural hearing loss, usually more prominent in the higher frequencies.
  • Hearing loss does not necessarily correlate with tumor size.
  • The speech discrimination score is usually markedly reduced in the affected ear and out of proportion to the measured hearing loss.
  • Common audiometry tests that are of current practice include:

Vestibular testing

  • Vestibular testing has limited utility as a screening test for the diagnosis of vestibular schwannoma because of the accuracy of evoked response audiometry.
  • When testing is performed, a decreased or absent caloric response on the affected side may be seen. When the tumor is small, though, a normal response is often seen.

Treatment

Treatment options for patients with a vestibular schwannoma include surgery and radiation therapy.

Surgery

Surgery generally results in satisfactory long-term control of vestibular schwannomas. There are three standard operative approaches.

Surgery
Retromastoid suboccipital (retrosigmoid) The suboccipital approach can be used for any size tumor with or without attempted hearing preservation.
Translabyrinthine The translabyrinthine approach has been recommended for acoustic tumors larger than 3 cm and for smaller tumors when hearing preservation is not an issue.
Middle fossa The middle fossa approach is suitable for small (<1.5 cm) tumors when hearing preservation is a goal.

Radiation therapy

Radiation therapy for patients with vestibular schwannoma include stereotactic radiosurgery (SRS), stereotactic radiotherapy (SRT), and proton beam therapy, as well as conventional fractionated radiation therapy.

Radiation therapy
Stereotactic radiosurgery
  • SRS is a technique that utilizes multiple convergent beams to deliver a high single dose of radiation to a radiographically discrete treatment volume, thereby minimizing injury to adjacent structures.
  • This can be accomplished with either the gamma knife or a linear accelerator.
  • Radiosurgery is a viable treatment option for selected patients with smaller tumors (<3 cm) or for enlarging tumors in patients who are not candidates for surgery
Stereotactic radiotherapy
  • Fractionated SRT utilizes focused doses of radiation given over a series of treatment sessions.
  • The intent is to reduce radiation injury to critical neural structures while preserving tumor control.
Proton beam therapy
  • Proton beam therapy may provide maximal local tumor control while minimizing cranial nerve injuries.
  • The physical characteristics of the beam result in the majority of the energy being deposited at the end of a linear track (the Bragg peak), with the dose falling rapidly to zero beyond the Bragg peak.
  • Thus, the use of proton beam therapy permits the delivery of high doses of radiation therapy to the target volume while limiting the "scatter" dose received by surrounding tissues.

References